摘要
AD组血浆的NAbs-ASC水平低于对照组(P <0.05),总胆固醇水平高于对照组(P <0.05)。Spearman相关性分析显示,NAbs-ASC水平与总胆固醇水平呈负相关(rs =-0.290,P <0.05),认知功能水平与总胆固醇水平呈负相关(rs =-0.380,P <0.05),而与血浆NAbs-ASC水平呈正相关(rs =0.550,P <0.05)。多因素Logistic回归分析结果显示,总胆固醇升高为AD的危险因素[O^R =3.004(95% CI:1.075,8.396)],NAbs-ASC升高为AD的保护因素[O^R =0.998(95% CI:0.997,0.999)]。
阿尔茨海默病(Alzheimer's disease, AD)是一种以认知功能进行性下降为主要表现的神经退行性疾病,患者的认知、行为、情感及其他神经功能会出现不同程度的损
选取2022年10月—12月陆军军医大学大坪医院神经内科门诊38例AD患者及健康管理科38例为对照组。AD纳入标准:①45岁≤ 年龄< 85岁;②AD的诊断依据2018版NIA-AA标
受试者空腹抽取5 mL静脉血置于肝素抗凝管中,使用低速台式离心机(cenceTD5A-WS,湖南湘仪实验室仪器开发有限公司)2 000 r/min离心10 min,取上清液保存至-80 ℃冰箱。ELISA步骤如下:①标准品的稀释:把原倍标准品稀释为5个不同浓度。②加样:分别设空白孔(不加样品及酶标试剂)、标准孔、待测样品孔。在标准孔中加入标准品50 μL,待测样品孔中先加样品稀释液40 μL,然后再加待测样品10 μL。③温育:用封板膜封板后置于37 ℃条件下温育30 min。④配液:浓缩洗涤液稀释备用。⑤洗涤:弃去液体,加入洗涤液30 s后弃去,重复5次。⑥加酶:每孔加入酶标试剂50 μL,空白孔除外。⑦温育:操作同③。⑧洗涤:操作同⑤。⑨显色:每孔依次加入显色剂A与显色剂B各50 μL,轻轻震荡混匀,37 ℃避光显色10 min。⑩终止:每孔加终止液50 μL。⑪测定:酶标仪450 nm波长处测量各孔的吸光度值。ELISA试剂盒购自上海泛柯实业有限公司。
两组的性别构成、受教育年限、高血压占比、糖尿病占比、冠心病占比、脑卒中占比、吸烟占比、饮酒占比、甘油三酯水平比较,差异均无统计学意义(P >0.05)。两组的年龄、空腹血糖、TC水平、MMSE评分比较,差异有统计意义(P <0.05);AD组患者年龄低于对照组,空腹血糖、TC水平高于对照组,MMSE评分低于对照组。见
组别 | 男/女/例 | 年龄/(岁,x±s) | 受教育年限/[年, M(P25,P75)] | 高血压 例(%) | 糖尿病 例(%) | 冠心病 例(%) | 脑卒中 例(%) |
---|---|---|---|---|---|---|---|
AD组 | 12/26 | 67.18±1.77 | 9.0(6.0,12.0) | 18(48.65) | 9(25.00) | 5(13.20) | 2(5.60) |
对照组 | 15/23 | 72.18±1.34 | 7.5(7.5,9.75) | 20(52.60) | 11(28.90) | 10(26.30) | 5(13.20) |
| 0.517 | 2.247 | 1.729 | 0.119 | 0.146 | 1.766 | 1.247 |
P 值 | 0.472 | 0.028 | 0.084 | 0.730 | 0.702 | 0.184 | 0.264 |
组别 | 吸烟 例(%) | 饮酒 例(%) | 空腹血糖/[mmol/L, M(P25,P75)] | TC/(mmol/L,x±s) | 甘油三酯/[mmol/L, M(P25,P75)] | MMSE评分 [M(P25,P75)] |
---|---|---|---|---|---|---|
AD组 | 3(7.90) | 5(13.20) | 5.69(5.08,6.56) | 4.90±0.18 | 0.98(0.81,1.41) | 14(8,19) |
对照组 | 5(13.20) | 3(7.90) | 4.91(4.44,6.48) | 4.13±0.11 | 1.15(0.85,1.72) | 27(26,28) |
| 0.559 | 0.559 | 2.474 | 3.574 | 1.153 | 7.523 |
P 值 | 0.455 | 0.455 | 0.013 | 0.001 | 0.249 | 0.000 |
AD组患者的血浆NAbs-ASC水平为1 587.95 ng/L(1 329.43,1 901.92),对照组的血浆NAbs-ASC水平为2 650.95 ng/L(2 186.32,3 114.77),经秩和检验,差异有统计学意义(P <0.05);AD组患者低于对照组。见

图1 两组血浆NAbs-ASC水平的比较
Spearman相关性分析显示,NAbs-ASC与TC呈负相关(rs =-0.290,P =0.012);MMSE评分与TC呈负相关(rs =-0.380,P =0.000),与NAbs-ASC呈正相关(rs =0.550,P =0.000)。见



图2 NAbs-ASC和TC的相关性及两者与MMSE评分的相关性线性图
单因素一般Logistic回归分析显示,TC升高[O^R =2.532(95% CI:1.407,4.557)]为AD的危险因素(P <0.05);NAbs-ASC升高[O^R =0.998(95% CI:0.997,0.999)]、年龄[O^R =0.948(95% CI:0.902,0.995)]为AD的保护因素(P <0.05)。多因素一般Logistic回归分析(矫正性别、年龄、甘油三酯、高血压、冠心病、糖尿病、脑卒中、吸烟、饮酒、空腹血糖后)显示:TC升高[O^R =3.004(95% CI:1.075,8.396)]为AD的危险因素(P <0.05);NAbs-ASC升高[O^R =0.998(95% CI:0.997,0.999)]为AD的保护因素(P <0.05)。见

图3 一般Logistic回归分析AD的危险因素
本研究结果显示,AD患者血浆TC水平高于对照组,并且TC水平与MMSE评分呈负相关,提示TC升高与认知功能下降相关。本研究发现AD患者TC水平高于对照组,与既往研究结论一
ASC是炎症小体的重要接头蛋白,参与细胞焦亡、炎症、免疫反应等过程,是启动免疫反应的关键蛋白。研究发现ASC促进AD患者Aβ斑块聚集与神经原纤维缠结,可能是AD进展的驱动因
单因素一般Logistic回归分析显示,TC升高为AD的危险因素,NAbs-ASC升高为AD的保护因素;且矫正性别、年龄、甘油三酯、高血压、冠心病、糖尿病、脑卒中、吸烟、饮酒、空腹血糖后,多因素一般Logistic回归分析显示,TC升高仍为AD的危险因素,NAbs-ASC升高仍为AD的保护因素。这之前的研究结果:总胆固醇升高为AD的危险因素是一致
本研究样本量相对较小,未能进行亚组分析进一步明确性别及年龄可能带来的差异;也可能存在其他可能影响测量结果的因素,如前驱糖尿病、胰岛素抵抗、营养不良
综上所述,AD患者TC水平高于对照组而NAbs-ASC水平低于对照组,NAbs-ASC水平升高为AD的保护因素,TC水平升高为AD的独立危险因素,且两者呈负相关。但TC与NAbs-ASC呈负相关的机制目前并不清楚,需要进一步的研究阐明。
参 考 文 献
KNOPMAN D S, AMIEVA H, PETERSEN R C, et al. Alzheimer disease[J]. Nat Rev Dis Primers, 2021, 7(1): 33. [百度学术]
WEUVE J, HEBERT L E, SCHERR P A, et al. Prevalence of Alzheimer disease in US states[J]. Epidemiology, 2015, 26(1): e4-e6. [百度学术]
DEMARSHALL C A, NAGELE E P, SARKAR A, et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers[J]. Alzheimers Dement (Amst), 2016, 3: 51-62. [百度学术]
STORCK S E, HARTZ A M S, PIETRZIK C U. The blood-brain barrier in Alzheimer's disease[J]. Handb Exp Pharmacol, 2022, 273: 247-266. [百度学术]
ARSHAVSKY Y I. Alzheimer's disease: from amyloid to autoimmune hypothesis[J]. Neuroscientist, 2020, 26(5-6): 455-470. [百度学术]
FRANKLIN B S, BOSSALLER L, de NARDO D, et al. The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation[J]. Nat Immunol, 2014, 15(8): 727-737. [百度学术]
MCGUINNESS B, O'HARE J, CRAIG D, et al. Cochrane review on 'statins for the treatment of dementia'[J]. Int J Geriatr Psychiatry, 2013, 28(2): 119-126. [百度学术]
KONG N, XU Q, CUI W, et al. PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis[J]. Ann Transl Med, 2022, 10(22): 1205. [百度学术]
FU Y, YUAN J Y, SANG F, et al. Biejiajian pill ameliorates diabetes-associated atherosclerosis through inhibition of the NLRP3 inflammasome[J]. Evid Based Complement Alternat Med, 2022, 2022: 9131178. [百度学术]
FANG Q L, LI X P, WANG M M, et al. Walnut green husk ethanol extract improves gut microbiota and their metabolites associated with NLRP3 in non-alcoholic steatohepatitis[J]. Food Funct, 2022, 13(11): 6387-6403. [百度学术]
JACK C R, BENNETT D A, BLENNOW K, et al. NIA‐AA research framework: toward a biological definition of Alzheimer's disease[J]. Alzheimer's & Dementia, 2018, 14(4): 535-562. [百度学术]
SALAMI M, ALINAGHIPOUR A, DANESHVAR R, et al. Adapted MMSE and TYM cognitive tests: how much powerful in screening for Alzheimer's disease in Iranian people[J]. Aging Ment Health, 2020, 24(6): 1010-1017. [百度学术]
WANG P, ZHANG H H, WANG Y, et al. Plasma cholesterol in Alzheimer's disease and frontotemporal dementia[J]. Transl Neurosci, 2020, 11(1): 116-123. [百度学术]
FU J J, HUANG Y, BAO T, et al. Effects of sex on the relationship between apolipoprotein E gene and serum lipid profiles in Alzheimer's disease[J]. Front Aging Neurosci, 2022, 14: 844066. [百度学术]
SAKURAI H, HANYU H, SATO T, et al. Vascular risk factors and progression in Alzheimer's disease[J]. Geriatr Gerontol Int, 2011, 11(2): 211-214. [百度学术]
LI L, CAO D F, DESMOND R, et al. Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease[J]. Dement Geriatr Cogn Disord, 2008, 26(4): 384-390. [百度学术]
XIONG H Q, CALLAGHAN D, JONES A, et al. Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production[J]. Neurobiol Dis, 2008, 29(3): 422-437. [百度学术]
KOJRO E, GIMPL G, LAMMICH S, et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10[J]. Proc Natl Acad Sci U S A, 2001, 98(10): 5815-5820. [百度学术]
ZHANG X L, TONG T, CHANG A, et al. Midlife lipid and glucose levels are associated with Alzheimer's disease[J]. Alzheimers Dement, 2023, 19(1): 181-193. [百度学术]
HULSE J, BHASKAR K. Crosstalk between the NLRP3 inflammasome/ASC speck and amyloid protein aggregates drives disease progression in Alzheimer's and Parkinson's disease[J]. Front Mol Neurosci, 2022, 15: 805169. [百度学术]
WHITE C S, LAWRENCE C B, BROUGH D, et al. Inflammasomes as therapeutic targets for Alzheimer's disease[J]. Brain Pathol, 2017, 27(2): 223-234. [百度学术]
SARESELLA M, LA ROSA F, PIANCONE F, et al. The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease[J]. Mol Neurodegener, 2016, 11: 23. [百度学术]
VENEGAS C, KUMAR S, FRANKLIN B S, et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer's disease[J]. Nature, 2017, 552(7685): 355-361. [百度学术]
CHEN H, DU Y, LIU S, et al. Association between serum cholesterol levels and Alzheimer's disease in China: a case-control study[J]. Int J Food Sci Nutr, 2019, 70(4): 405-411. [百度学术]
HELZNER E P, LUCHSINGER J A, SCARMEAS N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease[J]. Arch Neurol, 2009, 66(3): 343-348. [百度学术]
BAE J B, KIM Y J, HAN J W, et al. Incidence of and risk factors for Alzheimer's disease and mild cognitive impairment in Korean elderly[J]. Dement Geriatr Cogn Disord, 2015, 39(1/2): 105-115. [百度学术]
WEN H T, GRIS D, LEI Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol, 2011, 12(5): 408-415. [百度学术]